跳至主要内容
临床试验/ISRCTN14790675
ISRCTN14790675已完成4 期

An open, randomized comparative study of the efficacy and safety of using Ecomed (powder for oral suspension, containing azithromycin 100mg/5ml and lactulose 200mg/5ml, manufactured by JSC AVVA RUS, Russia) compared with Sumamed (powder for suspension, containing azithromycin 100mg/5ml, by Pliva Hrvatska doo, Croatia) in children with rhinosinusitis.

OJSC AVVA RUS0 个研究点目标入组 100 人开始时间: 2019年2月22日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Outpatient patients of both sexes from 3 to 14 years.
  • 2. Established diagnosis of Acute Purulent Sinusitis - evaluation of complaints, anamnesis, temperature, R-picture and rhinoscopy data - pus in the middle nasal passage and/or in the nasopharynx dome.
  • 3. Ability to regularly receive the studied drugs and perform research procedures.
  • 4. The Form of the Written Informed Consent to participate in the study is signed by one of the parents or the legal representative of the patient.
  • 5. Informing the patients' parents that during the entire study period the patient should not take prebiotics, probiotics, synbiotics, sorbents.

排除标准

  • 1. Intolerance to azalides, macrolides and other components of the drug.
  • 2. Administration of antibacterial drugs, including sulfonamides, within 28 days before the start of screening.
  • 3. Complicated course of infectious diseases of the upper and lower respiratory tract.
  • 4. Bacterial infection of another location, requiring the administration of antibiotics.
  • 5. Oncological disease without remission, at least for 5 years before the start of the study.
  • 6. Epilepsy, febrile convulsions in history.
  • 7. Impaired immunity according to anamnesis.
  • 8. Immunodeficiency.
  • 9. Active neoplastic process.
  • 10. Any other serious illness or condition that could jeopardize patient safety, affect life expectancy, or hinder successful treatment or monitoring of a patient according to the protocol.
  • 11. The reluctance of the child or his legal representatives to participate in clinical research.
  • 12. Drug use, alcoholism, mental illness of the legal representative of the patient.
  • 13. Participation in other clinical studies of medical drugs less than 3 months before the start of the study.

研究者

发起方
OJSC AVVA RUS

相似试验